A Study to Evaluate the Safety and Tolerability of EP0089

Exclusion Criteria

• •1. Known active CNS metastases and/or leptomeningeal disease and/or carcinomatous meningitis.
• •2. Recent major surgery
• •3. Recent live or live-attenuated vaccine ≤ 30 days prior to the first dose
• •4. Current active, or history of, autoimmune disease that requires or required systemic treatment (ie, with disease modifying agents, corticosteroids, or immunosuppressive drugs) within 2 years prior to starting study treatment.
• •5. Prior severe hypersensitivity reaction to mAbs
• •6. Previous \> Grade 2 peripheral neuropathy.
• •7. Significant neurological condition eg stroke, transient ischaemic attack (in the last 12 months), epilepsy, head trauma, brain surgery or prior history of any significant psychiatric disorder
• •9\. Current active, or history of, autoimmune disease that requires or required continuous treatment within 2 years prior to starting study treatment
• •10\. Receiving chronic systemic steroid therapy (\> 10 mg /day of prednisone or equivalent) or any other form of immunosuppressive therapy ≤ 7 days prior the first dose of study drug. Topical or inhaled steroids are permitted.
• •11\. Any prior immune-mediated or immune-related adverse events related to treatment with immune-modulatory agents that caused permanent discontinuation of the agent, that were ≥ Grade 3 in severity or in the opinion of the Investigator would otherwise jeopardise patient safety in this study.
• •12\. One or more clinically significant (ie, active) cardiovascular diseases, myocardial infarction, or unstable angina (≤ 6 months prior to first administration of study drug)